IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns(National Institute on Alcohol Abuse and Alcoholism), Mehdi Farokhnia(National Institutes of Health), Lorenzo Leggio(National Institute on Drug Abuse), Leandro F. Vendruscolo(National Institute on Drug Abuse), Elizabeth H. Tressler(National Institutes of Health)
Cited by 75
Related Papers
Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay
|Molecular Psychiatry|2017|241
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
|JCI Insight|2023|200
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review
|Pharmacological Reviews|2022|155
N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia
|Clinical Neuropharmacology|2013|154
Comparing the efficacy and safety of<i>Crocus sativus</i>L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial
|Human Psychopharmacology Clinical and Experimental|2014|151